A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug.
- DOI
- 10.1080/13543784.2026.2619604
- Published
- 2026 Jan-Feb
- Container
- Expert opinion on investigational drugs
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/13543784.2026.2619604,
title = {A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug.},
author = {Lu M and Chen J and Zhang H and Xu J and Li X and Hu Y and Liu J and Ai C and Shi C and Geng G and Ma Z and Niu J and Ding Y},
year = {2026},
journal = {Expert opinion on investigational drugs},
doi = {10.1080/13543784.2026.2619604},
url = {https://doi.org/10.1080/13543784.2026.2619604}
}RIS
TY - JOUR TI - A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug. AU - Lu M AU - Chen J AU - Zhang H AU - Xu J AU - Li X AU - Hu Y AU - Liu J AU - Ai C AU - Shi C AU - Geng G AU - Ma Z AU - Niu J AU - Ding Y PY - 2026 JO - Expert opinion on investigational drugs DO - 10.1080/13543784.2026.2619604 UR - https://doi.org/10.1080/13543784.2026.2619604 ER -
APA
M, L., J, C., H, Z., J, X., X, L., Y, H., J, L., C, A., C, S., G, G., Z, M., J, N., & Y, D. (2026). A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug.. Expert opinion on investigational drugs. https://doi.org/10.1080/13543784.2026.2619604
Source records
- pubmed · retrieved 2026-09-26T14:12:11.444Z
- europe-pmc · retrieved 2026-09-26T14:12:11.438Z